Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
HOUSTON, April 20, 2018 -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, including 1,200,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a public offering price of $7.50 per share. The aggregate offering size was $69.0 million, before deducting the underwriting discounts and commissions and other offering expenses.
Citigroup and Jefferies acted as lead book-running managers for the offering. Guggenheim Securities, Ladenburg Thalmann and Raymond James acted as co-managers.
The securities described above were offered by Bellicum pursuant to a shelf registration statement filed by Bellicum with the Securities and Exchange Commission (SEC), which was declared effective on July 12, 2017. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available for free on the SEC’s website at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus related to this offering may be obtained from: Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 821-7388, or by e-mail at [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Bellicum Pharmaceuticals, Inc.
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including CAR-T, TCR, and hematopoietic stem cell transplantation (HSCT) therapies. Bellicum is based in Houston, Texas.
Source: Bellicum Pharmaceuticals
Investors: Bellicum Pharmaceuticals, Inc. Alan Musso, CFO 832-384-1116 [email protected] Media: BMC Communications Brad Miles, 646-513-3125 [email protected]
